Discover Other news:

Diamond Acquires PharmaCentral to Strengthen Pharmacovigilance Division and Enhances Senior-level Expertise

21 April 2020


AUTHOR: Maureen Graham


Harlow, Essex, UK, 22 April 2020: Diamond Pharma Services (“Diamond” or “the Company”), a leading technical services and regulatory affairs consulting group, today announced its pharmacovigilance division, Diamond PV Services, has acquired PharmaCentral (, an innovative pharmacovigilance services and medical affairs business based in Dublin, Ireland. The acquisition will expand Diamond’s presence in Europe and enhance the senior-level expertise within its pharmacovigilance team.

PharmaCentral offers a wide range of pharmacovigilance consultancy services, based on a wealth of experience in pharmacovigilance and medical affairs in both pharma and CRO environments. The acquisition of PharmaCentral forms part of Diamond’s growth strategy for its pharmacovigilance division, which has achieved a Compound Annual Growth Rate (CAGR) in revenues of 27% over the last three years. This rapid expansion of Diamond’s pharmacovigilance senior level team is required to support clients from Diamond’s regulatory affairs business in specialist areas such as gene and cell therapies.

Diamond Pharma Services provides Regulatory Affairs, Pharmacovigilance and Compliance & Quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licences throughout all stages of a product’s life cycle. Diamond will continue to expand its presence in Dublin through 2020, with recruitment across all three of its divisions.

David Boyd, Managing Director, Diamond PV Services Ltd, said: “We have seen strong organic growth over the last three years, which has driven us to evaluate our resources, including our in-house expertise, processes and systems. This acquisition will help support the next phase of growth, representing a step change in our senior team. Having worked closely with PharmaCentral over the past year I am confident that they share our culture of flexibility, quality and accessibility, and am hugely excited that they are joining Diamond to deliver our shared vision of helping our clients manage their regulatory responsibilities in a constantly evolving environment.”

Catherine Kenny, Co-founder of PharmaCentral LLP, commented: “This is an incredibly meaningful milestone for PharmaCentral. The cultural fit we have found between the two businesses, and our shared views on the growth areas within pharmacovigilance have created synergistic opportunities for both companies. PharmaCentral has spent a number of years building strong customer relationships and a reputation for quality. Together we will capitalise on those strengths to significantly increase our capabilities and service offerings. The PharmaCentral team is excited to join Diamond Pharma Services and we look forward to the future.”

About Diamond Pharma Services
Diamond Pharma Services (“Diamond”) is a regulatory affairs and product development consultancy headquartered in the UK, with offices in Europe as well as a US subsidiary.

Diamond’s skilled team of qualified regulatory professionals has many years’ experience in regulatory, pharmacovigilance, compliance and quality, and pharmaceutical/biologics technical development.

Diamond provides support from early stage development through to life cycle management of approved products, across all therapeutic areas, medicinal products, and devices; including small molecule and next generation biologics, through to cell and gene therapy products.

Diamond has been twice recognised by TOPRA (The Organisation for Professionals in Regulatory Affairs), for excellence and innovation in EU regulatory affairs.

About PharmaCentral
PharmaCentral offers a wide range of pharmacovigilance consultancy services with the necessary tools and expertise to assist clients in monitoring the safety of marketed medicinal products and meeting regulatory reporting requirements. PharmaCentral partners with clients from start to finish, focusing on their needs while developing effective strategies and producing high quality and timely deliverables and outputs. With a wealth of experience in pharmacovigilance and medical affairs gained in both pharma and CRO, PharmaCentral can create tailor-made service packages based on specific pharmacovigilance requirements.


21 April 2020


AUTHOR: Maureen Graham